American Journal of Transplantation最新文献

Reply to "Real-world registry evidence beware: Old-world risk analysis may not be applicable to new world belatacept utilization". 回复“真实世界的注册证据注意：旧世界的风险分析可能不适用于新世界的延迟接受利用”。

IF 8.9 2区医学

American Journal of Transplantation Pub Date : 2025-05-24 DOI: 10.1016/j.ajt.2025.05.027

Shyfuddin Ahmed, Christopher Blosser, Ajay K Israni, Eric A Engels

引用次数: 0

Graft Survival in Single versus Bilateral Lung Transplantation for Emphysema. 肺气肿单肺移植与双肺移植的存活率比较。

IF 8.8 2区医学

American Journal of Transplantation Pub Date : 2025-05-24 DOI: 10.1016/j.ajt.2025.05.025

Darren E Stewart,Jessica M Ruck,Allan B Massie,Dorry L Segev,Melissa B Lesko,Justin C Chan,Stephanie H Chang,Travis C Geraci,Darya Rudym,Mark A Sonnick,Guido Barmaimon,Luis F Angel,Jake G Natalini

{"title":"Graft Survival in Single versus Bilateral Lung Transplantation for Emphysema.","authors":"Darren E Stewart,Jessica M Ruck,Allan B Massie,Dorry L Segev,Melissa B Lesko,Justin C Chan,Stephanie H Chang,Travis C Geraci,Darya Rudym,Mark A Sonnick,Guido Barmaimon,Luis F Angel,Jake G Natalini","doi":"10.1016/j.ajt.2025.05.025","DOIUrl":"https://doi.org/10.1016/j.ajt.2025.05.025","url":null,"abstract":"The benefits of bilateral lung transplantation (BLT) versus single lung transplantation (SLT) are still debated. One impediment to clinical recommendations is that BLT vs. SLT advantages may vary based on underlying disease. Since both options are clinically tenable in patients with emphysema, we conducted a comprehensive assessment of lung allograft survival in this population. Using U.S. registry data, we studied time to all-cause allograft failure in 8,092 patients 12 years or older transplanted from 2006 to 2022, adjusting for recipient, donor, and transplant factors by inverse propensity weighting. Median allograft survival was 6.6 years in BLT compared to 5.3 years in SLT, a 25% risk-adjusted survival advantage of 0.81.31.8 years. Risk-adjusted bilateral survival advantages varied between 0.9 and 2.4 years across eleven subgroups. Median allograft survival in BLT was 1.2 years greater than right SLT and 2.0 years greater than left SLT. During the 16-year study period, allograft survival steadily improved for BLT but not for SLT. Although the 25% BLT survival advantage pre-dated the pandemic, COVID-19 may have contributed to an apparent SLT survival decline. Recognizing the possible influence of residual confounding due to selection biases, these findings may aid offer decision-making when both donor lungs are available.","PeriodicalId":123,"journal":{"name":"American Journal of Transplantation","volume":"17 1","pages":""},"PeriodicalIF":8.8,"publicationDate":"2025-05-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144145969","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The transplant community braces for death by preventable infectious diseases 移植社区为可预防的传染病造成的死亡做准备

IF 8.9 2区医学

American Journal of Transplantation Pub Date : 2025-05-22 DOI: 10.1016/j.ajt.2025.05.006

Lara C. Pullen

引用次数: 0

Cell therapy with human IL-10-producing ILC2s enhances islet function and inhibits allograft rejection. 细胞治疗用人il -10产生ILC2s增强胰岛功能和抑制同种异体移植排斥反应。

IF 8.8 2区医学

American Journal of Transplantation Pub Date : 2025-05-22 DOI: 10.1016/j.ajt.2025.05.023

Sarah J Colpitts,Sinthuja Jegatheeswaran,Amanda Oakie,Siavash Mashhouri,Nadia Sachewsky,Humaira Murshed,Jessica A Mathews,Kyle T Reid,Paraish S Misra,Vivian C W Fung,Trevor W Reichman,M Cristina Nostro,C Bruce Verchere,Megan K Levings,Sarah Q Crome

{"title":"Cell therapy with human IL-10-producing ILC2s enhances islet function and inhibits allograft rejection.","authors":"Sarah J Colpitts,Sinthuja Jegatheeswaran,Amanda Oakie,Siavash Mashhouri,Nadia Sachewsky,Humaira Murshed,Jessica A Mathews,Kyle T Reid,Paraish S Misra,Vivian C W Fung,Trevor W Reichman,M Cristina Nostro,C Bruce Verchere,Megan K Levings,Sarah Q Crome","doi":"10.1016/j.ajt.2025.05.023","DOIUrl":"https://doi.org/10.1016/j.ajt.2025.05.023","url":null,"abstract":"Group 2 innate lymphoid cells (ILC2s) that produce IL-10 (IL-10+ILC2s) have demonstrated regulatory and tissue-protective properties in murine studies, but preclinical studies are lacking that explore the potential of human IL-10+ILC2s as a tolerance-promoting cell therapy for transplantation or autoimmunity. Here, we investigated whether human IL-10+ILC2s could enhance islet function and prevent allograft rejection in humanized mouse models of islet transplantation. In vitro, human IL-10+ILC2s did not display cytotoxicity towards allogeneic deceased-donor islets or stem cell-derived islet-like cells, and co-transplantation with IL-10+ILC2s significantly improved glucose control post-transplantation. Allogeneic IL10+ILC2s directly inhibited T cell-mediated cytotoxicity against islet-like cells in vitro, and in an antigen-specific transplant rejection model, prevented T cell-mediated rejection of deceased donor islet grafts. Effects were greater with allogeneic IL-10+ILC2s, as autologous cells did not inhibit T cell IFN-γ production or cytotoxic activity in vitro, and were not sufficient to prevent islet rejection in vivo.Collectively, these studies provide proof-of-principle that human IL-10+ILC2s have therapeutic potential for islet transplantation and type 1 diabetes, and support their use as an allogeneic regulatory cell therapy.","PeriodicalId":123,"journal":{"name":"American Journal of Transplantation","volume":"64 1","pages":""},"PeriodicalIF":8.8,"publicationDate":"2025-05-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144136806","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Unexpected incidental finding in a prospective living kidney donor 意外的意外发现一个潜在的活体肾脏捐赠者

IF 8.9 2区医学

American Journal of Transplantation Pub Date : 2025-05-22 DOI: 10.1016/j.ajt.2025.01.033

Vincenzo Villani, Rupak D. Kulkarni

引用次数: 0

Evaluation of the Stability of Organ Procurement Organization Performance Metrics. 器官采购组织绩效指标稳定性评价。

IF 8.8 2区医学

American Journal of Transplantation Pub Date : 2025-05-21 DOI: 10.1016/j.ajt.2025.05.024

Rocio Lopez,Sumit Mohan,James R Rodrigue,Susana Arrigain,Deena Brosi,Ryan Lavanchy,David Zingmond,Bruce Kaplan,Elizabeth A Pomfret,Jesse D Schold

{"title":"Evaluation of the Stability of Organ Procurement Organization Performance Metrics.","authors":"Rocio Lopez,Sumit Mohan,James R Rodrigue,Susana Arrigain,Deena Brosi,Ryan Lavanchy,David Zingmond,Bruce Kaplan,Elizabeth A Pomfret,Jesse D Schold","doi":"10.1016/j.ajt.2025.05.024","DOIUrl":"https://doi.org/10.1016/j.ajt.2025.05.024","url":null,"abstract":"In 2020, the Centers for Medicare and Medicaid Services (CMS) updated the Organ Procurement Organization (OPO) Conditions for Coverage, redefining deceased donor potential (DDP) as all inpatient deaths among patients 75 or younger with a primary cause of death consistent with organ donation, also called CALC (Cause, Age, and Location Consistent with donation). This study evaluates CALC performance metrics using 2018-20201 data from Centers for Disease Control (CDC) mortality data (currently used by CMS) and Agency for Healthcare Research and Quality's State Inpatient Databases (SID). We analyzed yearly performance variability, compared data sources, and examined the impact of CALC versus CALC-adjusted, which excludes donors with potential contraindications. There was significant year-to-year variability in CDC CALC tiers, with up to 40% of OPOs changing tiers annually. Between 20-43% of OPOs changed CALC performance tiers using SID compared to CDC. Additionally, while CALC and CALC-adjusted rates were correlated, 11-29% of OPOs changed performance tiers with adjustment. These differences identify opportunities for potential changes to create more stable and consistent OPO performance measures. Future research to refine these metrics to ensure they support the goal of continuing improvement in OPO performance to maximize organ donation and transplant rates is important.","PeriodicalId":123,"journal":{"name":"American Journal of Transplantation","volume":"39 1","pages":""},"PeriodicalIF":8.8,"publicationDate":"2025-05-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144130737","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Blunted Cardiac Reserve as a Marker of Cirrhotic Cardiomyopathy - Cardiac Outcomes Following Liver Transplantation and Comparison to the Existing Guidelines. 钝性心脏储备作为肝硬化心肌病的标志-肝移植后的心脏结局及与现有指南的比较。

IF 8.8 2区医学

American Journal of Transplantation Pub Date : 2025-05-19 DOI: 10.1016/j.ajt.2025.05.022

Benjamin Cailes,Eva-Louise Huber,Claudia Brick,Omar Farouque,Avik Majumdar,Ali Al-Fiadh,James Theuerle,Thalys S Rodrigues,Terase Lancefield,Matias B Yudi,Julian Yeoh,Adam Testro,Marie Sinclair,Anoop N Koshy

{"title":"Blunted Cardiac Reserve as a Marker of Cirrhotic Cardiomyopathy - Cardiac Outcomes Following Liver Transplantation and Comparison to the Existing Guidelines.","authors":"Benjamin Cailes,Eva-Louise Huber,Claudia Brick,Omar Farouque,Avik Majumdar,Ali Al-Fiadh,James Theuerle,Thalys S Rodrigues,Terase Lancefield,Matias B Yudi,Julian Yeoh,Adam Testro,Marie Sinclair,Anoop N Koshy","doi":"10.1016/j.ajt.2025.05.022","DOIUrl":"https://doi.org/10.1016/j.ajt.2025.05.022","url":null,"abstract":"Cirrhotic cardiomyopathy (CCM) is an underrecognized risk factor for cardiac events in patients undergoing liver transplantation (LT). Blunted cardiac reserve (BCR) is an emerging indicator of CCM, although it has not been integrated into diagnostic guidelines. This study assesses post-transplant cardiac outcomes and mortality in patients with BCR compared to current CCM diagnostic guidelines, focusing on diastolic indices. Consecutive patients undergoing liver transplant assessment were included. Of 978 patients screened with dobutamine stress echocardiography between 2010-2023, 481 (58.0%) progressed to LT, with 183 (38.0%) meeting BCR criteria and 117 (24.3%) meeting existing CCM diagnostic criteria. Thirty (6.2%) patients suffered a 30-day major adverse cardiovascular event (MACE), and 92 patients (19.1%) died on long-term follow-up. Following multivariate regression analysis, BCR was the strongest independent risk factor for post-operative MACE (HR 2.57 (1.13-5.85), p=0.024), heart failure exacerbations (HR 6.93 (1.46-33.01), p=0.015), and 30-day mortality (HR 9.69 (1.04-92.33), p=0.049). Addition of BCR to the existing guidelines improved MACE prediction (HR 5.81 (1.71-19.76) vs 2.59 (1.15-5.87), p=0.006), with a net reclassification improvement index of 41.9% (p=0.004) compared to existing guidelines alone. These results support the integration of a cardiac reserve assessment into CCM diagnostic criteria, and use in risk stratification of patients undergoing LT.","PeriodicalId":123,"journal":{"name":"American Journal of Transplantation","volume":"9 1","pages":""},"PeriodicalIF":8.8,"publicationDate":"2025-05-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144114227","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

FK506 prolongs corneal allograft survival and prevents dendritic cell infiltration in an MDSC-dependent manner. FK506以依赖mdsc的方式延长异体角膜移植存活并阻止树突状细胞浸润。

IF 8.8 2区医学

American Journal of Transplantation Pub Date : 2025-05-19 DOI: 10.1016/j.ajt.2025.05.018

Yingyi Liu,Yuerong Ren,Runxi Luo,Xiujuan Li,Limin Xie,Huanmin Kang,Yang Li,Xiaonan Dong,Yan He

{"title":"FK506 prolongs corneal allograft survival and prevents dendritic cell infiltration in an MDSC-dependent manner.","authors":"Yingyi Liu,Yuerong Ren,Runxi Luo,Xiujuan Li,Limin Xie,Huanmin Kang,Yang Li,Xiaonan Dong,Yan He","doi":"10.1016/j.ajt.2025.05.018","DOIUrl":"https://doi.org/10.1016/j.ajt.2025.05.018","url":null,"abstract":"FK506 (a.k.a. Tacrolimus) is one of most widely used immunosuppressive drugs in the postsurgery management of transplantation. To date, the cellular mechanism by which FK506 suppresses immune activation and elongates allograft survival remains largely unclear. Here, we employed a mouse model for corneal penetrating keratoplasty to interrogate this critical question. Administration of FK506 led to increased expansion myeloid-derived suppressor cells (MDSC) in recipient mice and prolonged survival of corneal allografts. In contrast, antibody-mediated depletion of MDSC abolished the FK506-mediated beneficial effects, which is associated with increased dendritic cell (DC) activation and recruitment to the graft bed and allografts. Of note, unlike continuous depletion and temporary early depletion (in the first week), delayed depletion of MDSC that started on day 8 posttransplant failed to disrupt the FK506-induced elongation of corneal allograft survival. Single-cell RNA sequencing analysis and immunofluorescence staining of corneal grafts reveal that FK506 reduced graft infiltration of immune cells including DC and T cells in an MDSC-dependent and temporal fashion. Moreover, depletion of MDSC reverted the FK506's suppression of DC maturation in the draining lymph node on day 7. Taken together, these findings indicate that FK506 prolongs allograft survival through induction of MDSC-mediated suppression of early DC activation.","PeriodicalId":123,"journal":{"name":"American Journal of Transplantation","volume":"136 1","pages":""},"PeriodicalIF":8.8,"publicationDate":"2025-05-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144114216","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Fatal acute respiratory distress syndrome caused by donor-derived human metapneumovirus after lung transplantation. 肺移植后供体源性人偏肺病毒致致致命性急性呼吸窘迫综合征。

IF 8.8 2区医学

American Journal of Transplantation Pub Date : 2025-05-17 DOI: 10.1016/j.ajt.2025.05.020

Solenne Hulot,Vincent Prunet,Benjamin Coiffard,Christine Zandotti,Céline Boschi,Xavier Benoit D'Journo,Sami Hraiech,Martine Reynaud-Gaubert,Philippe Colson,Nadim Cassir

引用次数: 0

Metabolic changes during cold ischemic preservation and reperfusion in porcine lung transplants. 猪肺移植冷缺血保存和再灌注过程中的代谢变化。

IF 8.8 2区医学

American Journal of Transplantation Pub Date : 2025-05-17 DOI: 10.1016/j.ajt.2025.05.021

Lubiao Liang,Michael K Hsin,Yajin Zhao,Aizhou Wang,Tiago Machuca,Jonathan Yeung,Marcelo Cypel,Shaf Keshavjee,Mingyao Liu

{"title":"Metabolic changes during cold ischemic preservation and reperfusion in porcine lung transplants.","authors":"Lubiao Liang,Michael K Hsin,Yajin Zhao,Aizhou Wang,Tiago Machuca,Jonathan Yeung,Marcelo Cypel,Shaf Keshavjee,Mingyao Liu","doi":"10.1016/j.ajt.2025.05.021","DOIUrl":"https://doi.org/10.1016/j.ajt.2025.05.021","url":null,"abstract":"Lung transplantation is a cornerstone in treating patients with end-stage lung disease, yet ischemia-reperfusion injury (IRI) poses significant complications in post-transplant recovery. This study aimed to understand the effects of donor type, cold ischemic time (CIT) and the reperfusion on metabolic changes in lung grafts. Porcine donor lungs underwent different CIT on ice: minimal time (control), 6 hours (CIT-6H), and 30 hours (CIT-30H). Additionally, lungs from brain death (BD) animals underwent 24-hour CIT (BD-CIT-24H). Both CIT-30H and BD-CIT-24H lungs underwent ex vivo lung perfusion for 12 hours, followed by left lung transplantation and reperfusion for 2 hours. Lung tissue samples were subjected to metabolomic analysis. Cold preservation induced time-dependent changes of certain metabolites. In BD-CIT-24H group, while most trends in metabolite levels were similar to the CIT-30H group, certain metabolite levels were markedly different. In CIT-30H lungs, reperfusion induced significant changes in the carbohydrate and amino acid pathways, along with consumption of energy substrates and reduction in antioxidants. BD donor lungs exhibited significantly reduction in lysophospholipids after reperfusion. Understanding these metabolic changes in the lung grafts shed lights on the mechanism of IRI, offering valuable insights for future development of targeted strategies to improve donor lung preservation and clinical outcome.","PeriodicalId":123,"journal":{"name":"American Journal of Transplantation","volume":"34 1","pages":""},"PeriodicalIF":8.8,"publicationDate":"2025-05-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144097700","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0